PK11000 is a stabilizer of mutant p53.1 It covalently binds to Cys182 and Cys277, increases the thermal stability, and inhibits the aggregation of the p53Y220C DNA-binding domain when used at a concentration of 1 mM. PK11000 selectively decreases the viability of mutant p53-expressing SW480 (p53R273H,P309S), NUGC-3 and Huh7 (p53Y220C), and MKN1 (p53V143A) cancer cells over wild-type p53-expressing NUGC-4, HuH-6, and SJSA-1 cancer cells. However, it is not selective between H1299 p53-/- and H1299 p53R175H non-small cell lung cancer (NSCLC) cells. PK11000 (15 µM) increases the expression of the p53 target genes p21 and PUMA and decreases the expression of the p53 target gene MDM2 in Huh7 and MKN1 cells. It also increases the levels of reactive oxygen species (ROS) in Huh7 and MKN1 cells.WARNING This product is not for human or veterinary use.
3A. General procedure for the synthesis of 5-chloro-2-(methylsulfonyl)pyrimidine-4-carboxylic acid: 5-chloro-2-(methylthio)pyrimidine-4-carboxylic acid (8.0 g, 39 mmol) was mixed with acetic acid (30 mL) and stirred, and 25% aqueous hydrogen peroxide (11.5 mL, 85 mmol) was added slowly dropwise over a controlled time period of 1 hour. The reaction mixture was stirred continuously at room temperature for 4 days. After completion of the reaction, the mixture was filtered and the resulting solid was washed with cold water (2 x 50 mL) and dried to afford the target compound 5-chloro-2-(methylsulfonyl)pyrimidine-4-carboxylic acid (5.8 g, 63% yield) as a white solid.1H NMR (400 MHz, CDCl3) δ 8.57 (s, 1H), 2.71 (s, 3H).
[1] Patent: US2007/270438, 2007, A1. Location in patent: Page/Page column 34
[2] Synthetic Communications, 2002, vol. 32, # 1, p. 153 - 157
[3] Synthetic Communications, 2007, vol. 37, # 13, p. 2231 - 2241
